Healing virus 'Rigvir' can double cancer survival rates

August 31, 2016, CORDIS
Healing virus ‘Rigvir’ can double cancer survival rates
Credit: Shutterstock

Strangely enough, cancer patients across the world seem to have come to terms with the fact that the most effective treatment against cancer - chemotherapy - actually destroys their immune system. In Latvia, however, a breakthrough virotherapy called Rigvir has been doing wonders since 2004. This new treatment, which breaks down cancer cells, simulates the immune system and promotes cancer cell suicide, will soon be brought to the rest of Europe partly thanks to EU support under Horizon 2020.

Rigvir officially received its H2020 SME Instrument grant in early August. Most recently, the treatment had shown 'surprisingly positive' outcomes for late cancer patients: A study published in July reveals that the administration of Rigvir in patients affected by melanoma stage IV M1C, small cell lung cancer stage IIIA and histiocytic sarcoma stage IV leads to a significant increase in and quality.

In Latvia, where it has been commercialised since 2004, Rigvir successfully passed all phases of clinical trials on 2 000 patients. Some 75 % of Latvian melanoma patients are already undergoing Rigvir treatment.

'There are millions of around the world who are in need of this unique cancer medicine,' said Rigvir's CFO Karlis Urbans. 'Rigvir is approved in three countries so far, however other patients can get virotherapy with Rigvir via medical tourism. I hope that this grant will make cancer virotherapy available for everyone who could benefit from it. Cancer patients deserve this safe, effective and humane cancer treatment.'

The treatment works on a wide variety of cancers including melanoma, colorectal, pancreatic, bladder, kidney, prostate, lung, uterine, lymphosarcoma, etc. This explains why it is also unleashing passions overseas: At the end of July, the Hope4Cancer Institute in California, USA, issued a press release announcing that it was now the first institution in the country to offer Rigvir virotherapy to its patients.

A healing virus

Rigvir was synthetised from the ECHO-7 virus, which can be found naturally in the intestines of young children. The virus selectively targets malignant cells, which it enters before multiplying through a process called oncolysis - eventually destroying the cancerous cell. Moreover, the virus makes the cancer visible to the patient's , enabling it to fight back.

Rigvir is administered by means of a series of injections over the course of three years. Although Latima - which develops and promotes the treatment - mentions mild side effects on its website, it specifies that the most common side-effect is a subfebrile temperature lasting one to three days. This contrasts with chemotherapy, infamous for the harm it causes to healthy cells.

The next step: EU registration

In order to become available in the whole of Europe, Rigvir has to go through European Medicine Agency (EMA) registration. The H2020 RIGVIR project, which is part of the SME instrument programme, will enable Latima to conduct a feasibility study, with results expected in January 2017. The company is hopeful that this project will be followed by phase 2 funding in order to perform the clinical trials necessary for registration with the EMA.

Explore further: Bristol-Myers drug fails lung cancer study, shares plunge

More information: Project website: rigvir.com/

Related Stories

Bristol-Myers drug fails lung cancer study, shares plunge

August 5, 2016
A blockbuster cancer treatment failed in a key study as the drug's maker, Bristol-Myers Squibb, attempts to extend its usage for lung cancer patients.

Second, unrelated malignancies strike 1 in 12 cancer patients

July 11, 2016
(HealthDay)—A new study indicates that 8 percent of patients—or one in 12—already diagnosed with one form of cancer will develop a second unrelated malignancy. The findings were published online July 5 in Cancer.

Pancreatic cancer trial to make tumours more sensitive to treatment

August 30, 2016
Cancer Research UK (CRUK) launches a first-of-its-kind pancreatic cancer clinical trial to make cancer cells more responsive to chemotherapy and radiotherapy, with University of Glasgow researcher Professor Jeff Evans as ...

Adjuvant chemotherapy in early-stage colon cancer may improve survival

July 15, 2016
Researchers and physicians have grappled with the role of "adjuvant," or post-surgery, chemotherapy for patients with early-stage colon cancer, even for cancers considered high risk. Now researchers from the University of ...

CTCA at Western Regional Medical Center advances combination immunotherapy clinical trial

January 8, 2016
Cancer Treatment Centers of America (CTCA) at Western Regional Medical Center (Western) in Goodyear, Arizona, has announced the launch of Phase II of the NivoPlus clinical trial, which combines the immunotherapeutic agent ...

Researchers use genetics to probe immune system's role in fighting cancer

August 25, 2016
To better understand the immune system's role in the fight against cancer, University of North Carolina Lineberger Comprehensive Cancer Center researchers have searched thousands of tumors for genetic signatures that might ...

Recommended for you

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...

A small, daily dose of Viagra may reduce colorectal cancer risk

March 19, 2018
A small, daily dose of Viagra significantly reduces colorectal cancer risk in an animal model that is genetically predetermined to have the third leading cause of cancer death, scientists report.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...

Joint supplement speeds melanoma cell growth

March 15, 2018
Chondroitin sulfate, a dietary supplement taken to strengthen joints, can speed the growth of a type of melanoma, according to experiments conducted in cell culture and mouse models.

Improved capture of cancer cells in blood could help track disease

March 15, 2018
Tumor cells circulating throughout the body in blood vessels have long been feared as harbingers of metastasizing cancer - even though most free-floating cancer cells will not go on to establish a new tumor.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.